0000000000621035

AUTHOR

Paolo Vercellini

showing 2 related works from this author

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

2021

Objective Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results M…

medicine.medical_specialtyendometrial neoplasmsCoronavirus disease 2019 (COVID-19)Endometrial Cancer; COVID-19; Uterine cancer; SARS-CoV-2covid-19; endometrial cancer; sars-cov-2; uterine cancer; female; humans; pandemics; retrospective studies; sars-cov-2; covid-19; endometrial neoplasmspandemicsEndometrial CancerNOCOVID-19; Endometrial Cancer; SARS-CoV-2; Uterine cancerRetrospective StudiePandemicmedicineUterine cancerhumansPatterns of carePandemicObstetricsbusiness.industrySARS-CoV-2Endometrial cancerObstetrics and GynecologyCOVID-19General Medicinemedicine.diseaseEndometrial Neoplasmsretrospective studiesSettore MED/40 - GINECOLOGIA E OSTETRICIAfemaleOncologyOriginal ArticleFemalebusinessHuman
researchProduct